
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8162615/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nature Medicine, 2021, 27, 1197-1204.	15.2	96
2	SH3TC2, a protein mutant in Charcot–Marie–Tooth neuropathy, links peripheral nerve myelination to endosomal recycling. Brain, 2010, 133, 2462-2474.	3.7	82
3	Mutations in INPP5K , Encoding a Phosphoinositide 5-Phosphatase, Cause Congenital Muscular Dystrophy with Cataracts and Mild Cognitive Impairment. American Journal of Human Genetics, 2017, 100, 523-536.	2.6	67
4	Myopathy in Marinesco–Sjögren syndrome links endoplasmic reticulum chaperone dysfunction to nuclear envelope pathology. Acta Neuropathologica, 2014, 127, 761-777.	3.9	51
5	Clinical presentation and proteomic signature of patients with <i>TANGO2</i> mutations. Journal of Inherited Metabolic Disease, 2020, 43, 297-308.	1.7	43
6	Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD. Molecular Therapy - Nucleic Acids, 2018, 13, 1-15.	2.3	41
7	Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. Lancet Neurology, The, 2020, 19, 522-532.	4.9	36
8	Intersection of Proteomics and Genomics to "Solve the Unsolved―in Rare Disorders such as Neurodegenerative and Neuromuscular Diseases. Proteomics - Clinical Applications, 2018, 12, 1700073.	0.8	33
9	Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy–like disease. Genetics in Medicine, 2018, 20, 1224-1235.	1.1	31
10	Cellular Signature of SIL1 Depletion: Disease Pathogenesis due to Alterations in Protein Composition Beyond the ER Machinery. Molecular Neurobiology, 2016, 53, 5527-5541.	1.9	30
11	The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. Human Molecular Genetics, 2018, 27, 1556-1564.	1.4	28
12	Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons. Human Molecular Genetics, 2018, 27, 2187-2204.	1.4	26
13	Mass spectrometryâ€based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy. Proteomics - Clinical Applications, 2018, 12, 1700071.	0.8	26
14	Neuromuscular Junction Changes in a Mouse Model of Charcot-Marie-Tooth Disease Type 4C. International Journal of Molecular Sciences, 2018, 19, 4072.	1.8	24
15	Inverted formin 2â€related Charcotâ€Marieâ€Tooth disease: extension of the mutational spectrum and pathological findings in Schwann cells and axons. Journal of the Peripheral Nervous System, 2015, 20, 52-59.	1.4	21
16	Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 2020, 7, 231-246.	1.1	20
17	Biochemical and pathological changes result from mutated Caveolin-3 in muscle. Skeletal Muscle, 2018, 8, 28.	1.9	19
18	Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144, 353-372.	3.9	19

#	Article	IF	CITATIONS
19	GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice. Human Molecular Genetics, 2018, 27, 3218-3232.	1.4	18
20	Protein signature of human skin fibroblasts allows the study of the molecular etiology of rare neurological diseases. Orphanet Journal of Rare Diseases, 2021, 16, 73.	1.2	18
21	Clinical and research strategies for limbâ€girdle congenital myasthenic syndromes. Annals of the New York Academy of Sciences, 2018, 1412, 102-112.	1.8	17
22	Proteomic Profiling Unravels a Key Role of Specific Macrophage Subtypes in Sporadic Inclusion Body Myositis. Frontiers in Immunology, 2019, 10, 1040.	2.2	17
23	PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 870-878.	0.9	16
24	Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients. Photoacoustics, 2022, 25, 100315.	4.4	16
25	MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide. Neuromuscular Disorders, 2017, 27, 1054-1064.	0.3	15
26	Tracking Effects of SIL1 Increase: Taking a Closer Look Beyond the Consequences of Elevated Expression Level. Molecular Neurobiology, 2018, 55, 2524-2546.	1.9	15
27	Molecular pathophysiology of human MICU1 deficiency. Neuropathology and Applied Neurobiology, 2021, 47, 840-855.	1.8	15
28	MYO9A deficiency in motor neurons is associated with reduced neuromuscular agrin secretion. Human Molecular Genetics, 2018, 27, 1434-1446.	1.4	14
29	ldentification of Candidate Protein Markers in Skeletal Muscle of Laminin-211-Deficient CMD Type 1A-Patients. Frontiers in Neurology, 2019, 10, 470.	1.1	14
30	Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes—A Retrospective Single Centre Cohort Study. Frontiers in Human Neuroscience, 2020, 14, 560860.	1.0	14
31	High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases. Brain, 2022, 145, 1507-1518.	3.7	14
32	Muscle Pathology as a Diagnostic Clue to Allgrove Syndrome. Journal of Neuropathology and Experimental Neurology, 2017, 76, 337-341.	0.9	13
33	Intracellular Lipid Accumulation and Mitochondrial Dysfunction Accompanies Endoplasmic Reticulum Stress Caused by Loss of the Co-chaperone DNAJC3. Frontiers in Cell and Developmental Biology, 2021, 9, 710247.	1.8	13
34	Cathepsin D as biomarker in cerebrospinal fluid of nusinersenâ€ŧreated patients with spinal muscular atrophy. European Journal of Neurology, 2022, 29, 2084-2096.	1.7	13
35	Diagnosing X-linked Myotubular Myopathy – A German 20-year Follow Up Experience. Journal of Neuromuscular Diseases, 2021, 8, 79-90.	1.1	12
36	NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. Brain, 2022, 145, 3999-4015.	3.7	12

3

#	Article	IF	CITATIONS
37	Modulation of Agrin and RhoA Pathways Ameliorates Movement Defects and Synapse Morphology in MYO9A-Depleted Zebrafish. Cells, 2019, 8, 848.	1.8	10
38	Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1). European Journal of Human Genetics, 2021, 29, 1348-1353.	1.4	10
39	Intellectual disability associated with craniofacial dysmorphism, cleft palate, and congenital heart defect due to a de novo <scp><i>MEIS2</i></scp> mutation: A clinical longitudinal study. American Journal of Medical Genetics, Part A, 2021, 185, 1216-1221.	0.7	9
40	SIL1 deficiency causes degenerative changes of peripheral nerves and neuromuscular junctions in fish, mice and human. Neurobiology of Disease, 2019, 124, 218-229.	2.1	7
41	Expanding the clinical and molecular spectrum of <scp><i>ATP6V1A</i></scp> related metabolic cutis laxa. Journal of Inherited Metabolic Disease, 2021, 44, 972-986.	1.7	7
42	INPP5K and SIL1 associated pathologies with overlapping clinical phenotypes converge through dysregulation of PHGDH. Brain, 2021, 144, 2427-2442.	3.7	7
43	Clinical Course, Myopathology and Challenge of Therapeutic Intervention in Pediatric Patients with Autoimmune-Mediated Necrotizing Myopathy. Children, 2021, 8, 721.	0.6	7
44	Three Individuals with PURA Syndrome in a Cohort of Patients with Neuromuscular Disease. Neuropediatrics, 2021, 52, 390-393.	0.3	7
45	Endoplasmic reticulumâ€stress and unfolded protein responseâ€activation in immuneâ€mediated necrotizing myopathy. Brain Pathology, 2022, 32, .	2.1	7
46	The Caveolin-3 G56S sequence variant of unknown significance: Muscle biopsy findings and functional cell biological analysis. Proteomics - Clinical Applications, 2017, 11, 1600007.	0.8	6
47	Severe neurodevelopmental disease caused by a homozygous TLK2 variant. European Journal of Human Genetics, 2020, 28, 383-387.	1.4	6
48	Autosomal recessive variants in TUBGCP2 alter the Î <sup>3</sup> -tubulin ring complex leading to neurodevelopmental disease. IScience, 2021, 24, 101948.	1.9	6
49	Identification of Cellular Pathogenicity Markers for SIL1 Mutations Linked to Marinesco-Sjögren Syndrome. Frontiers in Neurology, 2019, 10, 562.	1.1	5
50	Immunofluorescence-Based Analysis of Caveolin-3 in the Diagnostic Management of Neuromuscular Diseases. Methods in Molecular Biology, 2020, 2169, 197-216.	0.4	5
51	Homozygous WASHC4 variant in two sisters causes a syndromic phenotype defined by dysmorphisms, intellectual disability, profound developmental disorder, and skeletal muscle involvement. Journal of Pathology, 2021, , .	2.1	5
52	Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome. Frontiers in Molecular Neuroscience, 2020, 13, 594220.	1.4	5
53	Serum miRNAs as biomarkers for the rare types of muscular dystrophy. Neuromuscular Disorders, 2022, 32, 332-346.	0.3	5
54	Intragenic <i>DOK7</i> deletion detected by whole-genome sequencing in congenital myasthenic syndromes. Neurology: Genetics, 2017, 3, e152.	0.9	4

#	Article	IF	CITATIONS
55	Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo <i>PTEN</i> mutation. Neurology, 2018, 90, e1842-e1848.	1.5	4
56	Further evidence for POMK as candidate gene for WWS with meningoencephalocele. Orphanet Journal of Rare Diseases, 2020, 15, 242.	1.2	4
57	Muscular and Molecular Pathology Associated with SPATA5 Deficiency in a Child with EHLMRS. International Journal of Molecular Sciences, 2021, 22, 7835.	1.8	4
58	Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects. Orphanet Journal of Rare Diseases, 2022, 17, 29.	1.2	3
59	Identification of a novel homozygous <i>synthesis of cytochrome c oxidase 2</i> variant in siblings with earlyâ€onset axonal Charcotâ€Marieâ€Tooth disease. Human Mutation, 2022, 43, 477-486.	1.1	3
60	Dysregulation of GSK3β-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients. Journal of Neuromuscular Diseases, 2021, 8, 603-619.	1.1	2
61	SIL1-negative Marinesco-Sjögren syndrome: First report of two sibs from India. Journal of Pediatric Neurosciences, 2014, 9, 291.	0.2	2
62	New Insights into the Neuromyogenic Spectrum of a Gain of Function Mutation in SPTLC1. Genes, 2022, 13, 893.	1.0	2
63	A <i>de novo</i> <scp><i>CSDE1</i></scp> variant causing neurodevelopmental delay, intellectual disability, neurologic and psychiatric symptoms in a child of consanguineous parents. American Journal of Medical Genetics, Part A, 2022, 188, 283-291.	0.7	1
64	Phenotypical and Myopathological Consequences of Compound Heterozygous Missense and Nonsense Variants in SLC18A3. Cells, 2021, 10, 3481.	1.8	1
65	Circulating small RNA signatures differentiate accurately the subtypes of muscular dystrophies: small-RNA next-generation sequencing analytics and functional insights. RNA Biology, 2022, 19, 507-518.	1.5	1
66	Noninvasive Imaging in Pediatric Spinal Muscular Atrophy Patients Using Multispectral Optoacoustic Tomography: A Proof-of-Concept Study. Neuropediatrics, 2021, 52, .	0.3	0